Catabasis Pharmaceuticals to Present at Upcoming Investor and Industry Conferences
News Mar 29, 2012
-- Needham & Company’s 11th Annual Healthcare Conference, being held April 3-4 at the New York Palace Hotel in New York City. Dr. Jirousek will give a company presentation at 3:40 p.m. on Tuesday, April 3. This conference is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both public and private companies in sectors such as biotechnology, specialty pharmaceuticals, diagnostics and medical technology.
-- 2nd Diabetes Summit, being held April 19-20 at the Hyatt Harborside in Boston. Dr. Jirousek will present an overview of CAT-1004 as a novel new chemical entity for treating type 2 diabetes in the session “Clinical Drug Development in Diabetes” at 4:05 p.m. on Thursday, April 19. This conference will bring together the leading experts on diabetes from both industry and academia to discuss novel targets for diabetes, lessons to learn from current clinical drug development, and business strategies and opportunities under the current regulatory landscape.
-- Future Leaders in the Biotech Industry, being held April 20 at the Millennium Broadway Hotel & Conference Center in New York City. Dr. Jirousek will give a presentation on Catabasis’ novel approach to drug development at 3 p.m. The presentation will feature an overview of the company, proprietary chemistry platform and promising pipeline, including CAT-1004. This conference will showcase companies best positioned to provide market leadership and will continue to emphasize fresh investment opportunities.
Uptake of Controlled Release Drug Delivery Technology Set to Increase?News
The increasing access to healthcare facilities and the bolstering need for drugs to be used orally has been driving the consumption of generic drugs among people across the world, which, in turn, is fueling the need for controlled release technology for drug delivery to suffice the availability of drugs in small dosages.READ MORE
New Automated Screening Method for Identifying Drug CandidatesNews
Scientists at DESY have developed a new method that enables automated and fast screening of promising drug candidates.READ MORE
Metabolomic Profiling Identifies Taurine as New MS TherapeuticNews
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies. The discovery also highlights the potential for a technique called “metabolomic profiling,” which can identify useful endogenous metabolites the body already makes in small quantities, such as taurine, for new applications in drug therapies.READ MORE